[Interferon alfa 2b treatment decreases histological activity in children with chronic hepatitis B].

Abstract

Interferon alfa (IFN-alpha) is the only approved treatment for chronic hepatitis B (HBV) infection. In a non-controlled study 33 pediatric patients infected with HBV and in chronic phase of the disease were included and treated with 3 to 5 x 10(6) IU/m2 body surface of Interferon alpha 2b, 3 times per week, during 4 months. The objective was to evaluate the efficacy of the treatment in terms of the histological, biochemical and viral markers evolution of the patients. The patients were evaluated carrying out determinations of alanine aminotransferase (ALAT), HBsAg and HBeAg before treatment, at the end of the treatment and every 4 months during one year of follow-up. Liver biopsy and Knodell index determination were carried out at the beginning and upon concluding the follow-up. 39.3% of the patients concluded the treatment with normal ALAT values; 7% became HBsAg negative and 14.3% became HBsAg negative. These values ascended after follow-up to 51.5%, 11% and 37.5% respectively. The histological analysis evidenced a decrease of the Knodell index in 69% of the patients, an increase in 14.2%, and 13.8% did not show variation. Correlating the biochemical and histological responses, a favorable outcome was obtained in 36.4% of the patients, evidencing a remarkable reduction of the hepatic cytolysis. The treatment was well tolerated, being the fever the most frequent adverse events. The results confirm that interferon alfa seems to be an effective treatment for children with chronic hepatitis B.

• Authors: C Castañeda, Elsa García, B Grá, H Nodarse-Cuní, W García, Mabel Andrade, G Martínez, María Trujillo, Grisel Soto, Mayté Amoroto, Carmen Viada, P López-Saura
• Journal: Acta gastroenterologica Latinoamericana (Acta Gastroenterol Latinoam) Vol. 32 Issue 1 Pg. 35-42 (May 2002) ISSN: 0300-9033 [Print] Argentina
• Vernacular Title: Tratamiento con alfa 2b interferón disminuye actividad histológica en niños con hepatitis crónica B.
• PMID: 12136690 (Publication Type: Clinical Trial, Clinical Trial, Phase IV, Journal Article, Multicenter Study)

Chemical References

• Antiviral Agents
• Hepatitis B Surface Antigens
• Hepatitis B e Antigens
• Interferon alpha-2
• Interferon-alpha
• Recombinant Proteins
• Alanine Transaminase

Topics

• Alanine Transaminase (blood)
• Antiviral Agents (therapeutic use)
• Child
• Female
• Follow-Up Studies
• Hepatitis B Surface Antigens (blood)
• Hepatitis B e Antigens (blood)
• Hepatitis B, Chronic (drug therapy, pathology)
• Humans
• Interferon alpha-2
• Interferon-alpha (therapeutic use)
• Male
• Recombinant Proteins
• Statistics, Nonparametric
• Treatment Outcome